Prof Gareth Morgan discusses the role of maintenance therapy across the multiple myeloma (MM) disease spectrum from smoldering MM to NDMM to RRMM with Prof Antonio Palumbo and Dr Paul Richardson. Clinical data now available demonstrates the benefit of maintenance therapy in MM and the experts discuss results from the latest studies, how the myeloma treatment paradigm is evolving and expected changes to practice.

The group discusses the recent PETHEMA study presented by Dr Mateos at IMW 2011 which demonstrated that lenalidomide and dexamethasone delays progression of smouldering multiple myeloma. In newly diagnosed elderly patients, Professor Palumbo provides an overview of the MM015 trial and the experts also discuss the recently reported Intergroup Phase III Study (CALGB 100104) that demonstrated an overall survival benefit with lenalidomide as continuous therapy for patients with multiple myeloma. The group also discusses new drugs in development and their potential for extending options in maintenance treatment.

Professor Gareth Morgan (Institute of Cancer Research, UK)
Professor Antonio Palumbo (University of Turin, Italy)
Dr Paul Richardson (Dana Farber Institute, Boston, USA)


This programme was made possible with an educational grant provided by CELGENE.